Single Nucleotide Polymorphisms of MicroRNA Processing Machinery Genes and Outcome of Hepatocellular Carcinoma

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

| Citation       | Liu, Shuang, Jie An, Jianhong Lin, Yanli Liu, Lidao Bao, Wen Zhang, and Jian-Jun Zhao. 2014. “Single Nucleotide Polymorphisms of MicroRNA Processing Machinery Genes and Outcome of Hepatocellular Carcinoma.” PLoS ONE 9 [3]: e92791. doi:10.1371/journal.pone.0092791. http://dx.doi.org/10.1371/journal.pone.0092791. |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Published Version | doi:10.1371/journal.pone.0092791                                                                                                                                                                                                                       |
| Citable link    | http://nrs.harvard.edu/urn-3:HUL.InstRepos:12153014                                                                                                                                                                                                    |
| Terms of Use    | This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA                                                        |
Single Nucleotide Polymorphisms of MicroRNA Processing Machinery Genes and Outcome of Hepatocellular Carcinoma

Shuang Liu¹, Jie An¹, Jianhong Lin², Yanli Liu¹, Lidao Bao², Wen Zhang¹, Jian-Jun Zhao²*

¹ Department of Pathology, Bethune International Peace Hospital, Shijiazhuang, China, ²Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America

Abstract

MicroRNA (miRNA)-related single nucleotide polymorphisms (miR-SNPs) can affect cancer development, treatment efficacy and patients prognosis. We examined 6 miR-SNPs in miRNA processing machinery genes including exportin 5 (XPO5) (rs11077), Ran-GTPase (RAN) (rs14035), Dicer (rs3742330), Trinucleotide Repeat Containing 6B (TNRC6B) (rs9623117), GEMIN3 (rs197412), GEMIN4 (rs2740348) in 108 surgically resected HCC patients and evaluated the impact of these miR-SNPs on HCC outcome. Among the 6 SNPs, only the A/A genotype of rs11077 located in XPO5 3’UTR was identified to associated independently with worse survival in HCC patients by univariate analysis with relative risk, 0.395; 95% CI, 0.167–0.933; p = 0.034. This is the first study reporting that polymorphisms related to miRSNPs have prognostic value in hepatocellular carcinoma and identify the A/A genotype of rs11077 SNP site located in XPO5 3’UTR can help to predict worse prognosis in patients.

Introduction

Hepatocellular carcinoma (HCC) is the fifth most common cancer and is responsible for more than half a million deaths each year, which makes it the third leading cause of cancer deaths worldwide [1]. The severity of HCC and the lack of effective treatment strategies make the disease a major challenge. This disease is strongly associated with several risk factors, including chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, and alcohol abuse [2]. The incidence of HCC has increased steeply in Asia and Africa, where HBV and HCV infections are more prevalent than in other continents. HBV infection is a challenging health issue in China, where approximately 93 million people are HBV carriers and 30 million have chronic hepatitis B [2,3]. Alcohol abuse is also increasing in China, where ~6.6% of males and 0.1% of females in the population have been diagnosed with alcoholism [4]. Many of these people develop liver disease, such as alcoholic hepatitis and cirrhosis, which make them susceptible to HCC. Despite improved clinical detection methods and therapies, the prognosis of post-operative HCC patients is still poor, due to a high recurrence rate. While the molecular mechanism of HCC carcinogenesis is still not fully understood, there are many prognostic factors and predictors of recurrence associated with the disease, including tumour size, tumour quantity, cell differentiation, venous invasion and degree of inflammation [5–9].

MicroRNAs (miRNAs) are RNA molecules with lengths of ~22 nucleotides that act as posttranscriptional regulators of mRNA expression [10,11]. Over 1000 miRNAs have been identified in humans, and these miRNAs are responsible for regulating the expression of at least 30% of protein-coding genes. A growing body of evidence suggests that miRNAs play important roles in a broad range of biological processes, such as embryonic development, cellular differentiation, proliferation, apoptosis, cancer development and insulin secretion [10,11]. In the miRNA processing, long primary transcripts of miRNAs (pri-miRNAs) are processed in nucleus by the RNase III Drosha, transported to the cytoplasm by the nuclear transport factor exportin-5 (XPO5) and Ran-GTPase (RAN). In the cytoplasm, RNase III Dicer and transactivation-responsive RNA-binding protein (TRBP) mediate pre-miRNAs processing to release a 21-bp dsRNA, the RNA-induced silencing complex (RISC) including GEMIN3 and GEMIN4 will select one strand as the mature miRNA and guide mature miRNAs to their target miRNA sites [10,12–16]. MiRNA related single nucleotide polymorphisms (miR-SNPs), defined as single nucleotide polymorphisms (SNPs) in miRNA genes, miRNA binding site and miRNA processing machinery, can modulate miRNA and targeted genes expression so as to affect cancer development, therapeutic efficacy and patient’s prognosis [16–19].

In the present study, we genotyped 6 miR-SNPs in mir122-1 in miRNA processing machinery genes including XPO5 (rs11077), RAN (rs14035), Dicer (rs3742330), TNRC6B (rs9623117), GEMIN3 (rs197412), GEMIN4 (rs2740348) in 108 surgically treated HCC patients and evaluated the impact of these miR-SNPs on HCC outcome. The post-operated HCC patients enrolled in this study...
were followed up with regular visits by laboratory tests combined with ultrasound, contrast-enhanced computed tomography (CT) or contrast-enhanced magnetic resonance imaging (MRI). A miR-SNP in the 3'UTR region of XPO5 was found to be an independent prognostic marker for HCC outcomes.

### Materials and Methods

**Tissue specimens and DNA extraction**

Blood samples were collected at the Bethune International Peace Hospital from 108 HCC patients who underwent tumour resection in the Department of Hepatobiliary Surgery between

---

**Table 1. All the primers and probes used for genotyping of miR-SNPs.**

| Gene    | rs NCBi  | Primer sequence                  | Probe sequence                           |
|---------|----------|----------------------------------|------------------------------------------|
| XPO5    | rs11077  | A/G                              | S1 GTACCTCCAAGGAGCCAGGGCTGGGA            |
|         |          | F GAATCTGGTGACTCTAGAGGGGA        | S2 TTTGCCTCCAAAGGAGCCAGGGCTGGGA          |
|         |          | R GTGCCCTGAGGACCTTGGGA           | S3 AGTCTTTAGGCTAACATCCCTTTT              |
| RAN     | rs14035  | C/T                              | S1 TTGTGATGTTATGTTGTAATGGAGACC          |
|         |          | F GCACCTTCCTTCAATCTGTA           | S2 TTGTGATGTTATGTTGTAATGGAGACC          |
|         |          | R TAAACCAAGATTCAACCCAAAACC       | S3 TAAAACCAAGATGACATGATGGATT             |
| GEMIN4  | rs2740348| G/C                             | S1 TTTTTTTTTGGAGTAACAGGGGCCCCTTCCGAG    |
|         |          | F TGCCTCTGAGAAGAAGTGG            | S2 TTTTTTTTTGGAGTAACAGGGGCCCCTTCCGAG    |
|         |          | R GACTCAGGGATGGCTCTGTC           | S3 AGCCTTTTTTTGAGTAACAGGGGCCCCTTCCGAG   |
| TNRC6B  | rs9623117| C/T                             | S1 TTCTTCAGCTCTCTTACCTTAACTGAGC         |
|         |          | F TTCTTCAGCTCTCTTACCTTAACTGAGC  | S2 TTCTTCAGCTCTCTTACCTTAACTGAGC         |
|         |          | R CATTTAGTACACATCAGGCA           | S3 CTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT   |
| GEMIN3  | rs197412 | T/C                             | S1 TTATATGTATTGGTAAATGAAGTTAC           |
|         |          | F TAGAGAAACCTGGGAAATCA           | S2 TTATATGTATTGGTAAATGAAGTTAC           |
|         |          | R GAGAGCTTCTCTAGCAGTGA           | S3 TAAAGAGCTTCTCTCTCTCTCTCTCTCTCTCTCT   |
| Dicer1  | rs374330 | A/G                             | S1 TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  |
|         |          | F AAAAGGATGAGACGTCTCTAGTTTG      | S2 TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  |
|         |          | R GTGCAGAGATGCAGCTGGAATT        | S3 TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT |

F: represents forward primer for PCR.  
R: represents reverse primer for PCR.  
S1 and S2 represent probes match to different alleles of the SNP.  
S3 represents probes downstream of the SNP.

doi:10.1371/journal.pone.0092791.t001

**Table 2. Univariate analysis of clinical characteristics associated with post-operative survival with HCC by log-rank test.**

| Characteristics                  | No. cases | 3 years survival rate (%) | p value |
|----------------------------------|-----------|---------------------------|---------|
| Gender                           |           |                           |         |
| Male                             | 88        | 33.0                      | 0.052   |
| Female                           | 20        | 15.0                      |         |
| Age(years)                       |           |                           |         |
| ≤55                              | 56        | 34.6                      | 0.086   |
| >55                              | 52        | 25.0                      |         |
| Child classification             |           |                           |         |
| A                                | 94        | 34.0                      | 0.014   |
| B                                | 14        | 0.0                       |         |
| Portal vein thrombosis           |           |                           |         |
| No                               | 92        | 32.6                      | 0.003   |
| Yes                              | 16        | 12.5                      |         |
| Size of the tumor (diameter/cm)  |           |                           |         |
| ≤5                               | 44        | 47.7                      | 0.004   |
| >5                               | 64        | 17.2                      |         |
| TNM classification               |           |                           |         |
| I                                | 54        | 44.4                      | 0.000   |
| II                               | 43        | 16.3                      |         |
| III                              | 11        | 9.1                       |         |
| Rs11077                          |           |                           |         |
| AA                               | 93        | 24.7                      | 0.010   |
| AC+CC                            | 15        | 60.0                      |         |

doi:10.1371/journal.pone.0092791.t002
were genotyped using the Polymerase Chain Reaction - Ligase Detection Reaction (PCR-LDR) assay with the forward and reverse primers to amplify the DNA fragments flanking miR-SNPs using the sequence in the NCBI SNP database (http://www.ncbi.nlm.nih.gov/snp/). Polymerase Chain Reaction (PCR) was performed using a PCR Master Mix Kit according to the manufacturer's instructions (Promega, Madison, WI). The ligation was performed using the different probes matched to the miR-SNPs, and the ligated products were separated using the ABI PRISM Genetic Analyzer 3730XL (Applied Biosystems, Foster City, CA). Polymorphisms were confirmed based on the length difference of ligated products. All the primers and probes were listed in Table 1.

**Statistical analysis**

Statistical analyses were performed using the SPSS 18.0 software package (SPSS Company, Chicago, IL). Overall survival (OS) was calculated from the time of operation to last follow-up or death. Survival curves were calculated using the Kaplan-Meier method, and comparisons between the curves were analyzed using the log-rank test. Multivariate survival analysis was performed using a Cox proportional hazards model. A p value of <0.05 was considered statistically significant.

**Results**

**Correlation between clinical characteristics of HCC patients and overall survival**

The relationship between the overall survival during the 3-year follow-up and patients' clinical characteristics was analysed using the Kaplan–Meier method and the log-rank test. No differences were detected in overall survival time among HBV-HCC, HCV-HCC and alcohol-related HCC patients; therefore, we assessed them together in further analyses. Sex and age were not statistically significant predictors of post-operative survival time; however, tumor size, tumor stage, child classification, portal vein thrombosis and rs11077 SNP site located in XPO5 3’UTR were correlated with survival time in these patients (Table 2).

**Association of XPO5 polymorphisms with HCC outcome**

We genotyped these 6 miR-SNP of miRNA processing machinery genes including XPO5 (rs11077), RAN (rs14035), Dicer (rs3742330), TNRC6B (rs9623117), GEMIN3 (rs197412), GEMIN4 (rs2740346) in 108 HCC patients and 80 healthy controls, no statistically significant association (p > 0.05) between patients and healthy controls was detected (data not shown). We subsequently evaluated their association for post-operational survival with Kplan-Meier methods. Among 6 SNPs, only rs11077 SNP site of XPO5 genes had prognostic impact on post-operative survival of HCC with log-rank test analysis, the
three-year survival rate of A/A, and A/C+C/C ge patients were 24.7% and 60% respectively. The patients with A/A genotype of XPO5 rs11077 SNP site show a shorter overall survival compared with that of A/C+C/C genotypes (p = 0.010) as shown in Figure 1. We then performed multivariate analysis with the Cox proportional hazards model for HCC outcome associated clinical characteristics and rs11077 SNP genotypes in these patients. As shown in Table 3, the rs11077 SNP was identified as an independent predictor of HCC outcome (relative risk, 0.959; 95% CI, 0.167–0.933; p = 0.034). Tumor stage, Child classification, but not portal vein thrombosis and size of tumor, were identified as independent predictive factors for HCC outcome. These data further demonstrated that the A/A genotype of rs11077 located in XPO5 3'UTR was associated with worse survival in HCC patients.

Discussion

In the present study, we report for the first time that miR-SNPs have predictive value on post-operative survival of HCC patients. The miR-SNP in miRNA processing machinery genes of XPO5 are involved in the prognosis of HCC outcome. XPO5 is found in the nuclear membrane and mediates the transport of pre-miRNA between the nuclear and cytoplasmic compartments so as to adjust the whole miRNA expression level. Knock down XPO5 expression leads to reduced miRNA levels [20]. A mutated and inactive XPO5 resulted in reduced miRNA processing and decreased miRNA target inhibition, the restored XPO5 seemed to act as a tumor suppressor to reverse the impaired export of premiRNA in colon cancer [21]. The miR-SNP of rs11077 of XPO5 has been identified for its association with the cancer risk of esophageal cancer as well as the outcome of non-small-cell lung cancer and multiple myeloma [16–19,22]. Nevertheless, the mechanism how this SNP modified the HCC survival remain unclear, this SNP located in 3'UTR of XPO5 might affect miRNA stability and associated with alter expression of XPO5. The altered XPO5 expression may affect the miRNAs as a whole, leading to overall suppression of miRNA expression profiles thereby mediates the HCC survival. The fact that rs11077 C/C genotype show association with reduced Renilla expression in a Renilla luciferase 3'UTR reporter system implies that this SNP could modulate XPO5 expression so as to result in overall expression of miRNA in multiple myeloma cells [18]. Even though our results were concordant with the previous studies in non-small-cell lung cancer and multiple myeloma that A/C or C/C genotype of rs11077 associated with better outcome. Given the differential cell of origin for cancers and differential cell type specificity of miRNA transcriptomes, it is reasonable to assume that the effects of miR-SNP will be modulated in a cell type-specific manner. The role of XPO5 in hepatocellular cancer and the noncoding RNA including miRNA binding at this SNP site to mediate XPO5 expression need to be further investigated.

In summary, this is the first report investigating miR-SNPs involved in the miRNA network in liver cancer. A polymorphism in the binding site for diverse miRNA clusters in XPO5 was associated with a significantly OS in hepatocellular carcinoma patients. MiR-SNPs emerged as new promising markers for disease progression in cancer. Although miR-SNP studies for miRNA processing machinery genes are still preliminary, our results are encouraging, as they indicate that miR-SNPs could be used as cancer prognosis marker. However, the results from this study require validation in another larger HCC cohort study and in laboratory-based functional studies. MicroRNAs have been emphasized as a key factor in patients’ susceptibility to therapeutic response in many complex diseases, including cancer [23]. The analysis of genetic polymorphisms in miRNA processing genes may help to identify patient subgroups with poor prognoses and may, accordingly, help to refine therapeutic decisions regarding HCC patients.

Author Contributions

Conceived and designed the experiments: SL, JJZ. Performed the experiments: SL, JA, JL, LB, WZ, JJZ. Analyzed the data: SL, JJZ. Contributed reagents/materials/analysis tools: SL, JJZ. Wrote the paper: SL, JJZ.

References

1. Gomaa AI, Khan SA, Toleldo MB, Waked I, Taylor-Robinson SD (2008) Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. Clin J Gastroenterol 14: 490–493. 1
2. Caldwell S, Park SH (2009) The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol 44 Suppl 19: 96–101.
3. Yao GB (2000) Management of hepatitis B in China. J Med Virol 61: 392–397.
4. Lu L, Wang X (2008) Drug addiction in China. Ann N Y Acad Sci 1141: 304–317.
5. Maki A, Kono H, Gupta M, Asakawa M, Suzuki T, et al. (2007) Predictive power of biomarkers of oxidative stress and inflammation in patients with hepatitis C virus-associated hepatocellular carcinoma. Ann Surg Oncol 14: 1182–1190.
6. Okada S, Shimada K, Yamamoto J, Takayama T, Kosuge T, et al. (1994) Predictive factors for postoperative recurrence of hepatocellular cancer. Gastroenterology 106: 1618–1624.
7. Minagawa M, Makuchi M, Takayama T, Kukudo N (2003) Selection criteria for repeat hepatorectomy in patients with recurrent hepatocellular carcinoma. Ann Surg 238: 703–710.
8. Wang C, Zhang F, Fan H, Peng L, Zhang R, et al. (2011) Sequence polymorphisms of mitochondrial D-loop and hepatocellular carcinoma outcome. Biochem Biophys Res Commun 406: 493–496.
9. Guo Z, Wu C, Wang X, Wang C, Zhang R, et al. (2012) A polymorphism at the miR-502 binding site in the 3‘-untranslated region of the histone methyltransferase SET8 is associated with hepatocellular carcinoma outcome. Int J Cancer 131: 1316–1322.
10. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281–297.
11. Ambros V (2004) The functions of animal microRNAs. Nature 431: 350–355.
12. Cullen BR (2004) Transcription and processing of human microRNA precursors. Mol Cell 16: 861–865.
13. Lee Y, Ahn C, Han J, Choi H, Kim J, et al. (2003) The nuclear RNAse III Drosha initiates microRNA processing. Nature 425: 415–419.
14. Yi R, Qin Y, Macara IG, Cullen BR (2003) Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 17: 3011–3016.
15. Cherendimada TP, Gregory RI, Kumaraswamy E, Norman J, Cooch N, et al. (2005) TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 436: 740–744.
16. Ryan BM, Rohlhe AI, Harris CC (2010) Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 10: 389–402.
17. Campayo M, Navarro A, Vinasol N, Tejero R, Munoz C, et al. (2011) A dual role for KRT81: a miR-SNP associated with recurrence in non-small-cell lung cancer and a novel marker of squamous cell lung carcinoma. PLoS One 6: e22509.
18. de la Rua EA, Navarro A, Tejero R, Tovar N, Diaz T, et al. (2012) Impact of MiRSNPs on survival and progression in patients with multiple myeloma undergoing autologous stem cell transplantation. Clin Cancer Res 18: 3697–3704.
19. Boni V, Zarate R, Villa JC, Baudros E, Gomez MA, et al. (2011) Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan. Pharmacogenomics J 11: 429–436.
20. Landi E, Guttinger S, Calado A, Dahlberg JE, Kutay U (2004) Nuclear export of microRNA precursors. Science 303: 95–98.
21. Melo SA, Mosteiro C, Rojo S, Calin GA, Rossi S, et al. (2010) A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer Cell 18: 303–315.
22. Ye Y, Wang KK, Gu J, Yang H, Lan J, et al. (2008) Genetic variations in microRNA-related genes are novel susceptibility loci for esophageal cancer risk. Cancer Prev Res (Phila) 1: 460–469.
23. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, et al. (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7063–7070.